Abstract
Adverse drug reaction (ADR) is a serious life-threatening event and toxic epidermal necrolysis (TEN) is a serious ADR where severe skin lesions like, blisters with oral mucosal bleeding (OMB) are most common characteristics. Both watery blisters and OMB are painful conditions in TEN and considered as common source of infections. N-acetylcysteine (NAC) has anti-inflammatory property and the objective of this study was to observe the clinical response of NAC in the TEN-associated lesions management. For this study, we considered 17 patients those were suffering from TEN and admitted in the intensive care unit. Those 17 patients were distributed into 2 groups (A and B), where patients of group-A (n=7) treated with NAC while group-B's patients (n= 10) did not get NAC therapy. As a result, in group-A, 6 (85.71%; n=7) patients were found with complete remission of blisters and OMB progression within the 72 hours with 100% 10-day complete healing rate, whereas 60% patients in group-B (n= 10) required >72 hours for complete remission with 80% 10-day complete healing rate. So, NAC can be an effective therapy for prompt healing of life-threatening TEN-associated severe skin lesions.
Highlights
Adverse drug reaction (ADR) is an unpleasant and unpredictable skin reaction to medication that can affect 2-3% of all hospital admitted patients, which may be up to 8.25%, and among those events, 2% reactions are severe and become fatal [1, 2]
We considered 17 patients completely clear till today and is considered as a those were suffering from toxic epidermal necrolysis (TEN) and admitted in the biochemically complex immune-mediated reaction
Among those 21 patients, initially 2 patients were discontinued from the study
Summary
Adverse drug reaction (ADR) is an unpleasant and unpredictable skin reaction to medication that can affect 2-3% of all hospital admitted patients, which may be up to 8.25%, and among those events, 2% reactions are severe and become fatal [1, 2]. After admitting in ICU, all the ADR-related culprit drugs were identified and it was assured that none of those was present currently in patients’ medication lists. Among those 21 patients, initially 2 patients were discontinued from the study (one patient died within 24 hours after admitting in ICU and another patient came from another hospital where he got the initial treatment for TEN and skin lesions). Study was completed with 7 patients in group-A and 10 patients in group-B
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
